# InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reports Positive VALID-ECG Study Results Supporting 12-Lead ECG Technology

HeartBeam (NASDAQ: BEAT) announced that its synthesized 12-lead ECG technology met clinical endpoints in the VALID-ECG pivotal study, achieving a 93.4% diagnostic agreement with standard 12-lead ECGs for arrhythmia assessment. Results were presented by Dr. Thomas Deering of Piedmont Heart Institute during the Heart Rhythm Society’s annual conference. HeartBeam’s 3D ECG technology, designed to fit into a credit card-sized device, aims to bring hospital-grade cardiac insights to patients anywhere, with commercialization planned following anticipated FDA clearance.

 To view the full press release, visit https://ibn.fm/ABvdX

 About HeartBeam Inc.

 HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com .

 NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-heartbeam-inc-nasdaq-beat-reports-positive-valid-ecg-study-results-supporting-12-lead-ecg-technology/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/heartbeam-s-3d-ecg-technology-achieves-major-milestone-in-clinical-study/d656543ae1604163be75f9af1f27744f) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1kaosqm/heartbeams_3d_ecg_technology_achieves_major/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/254/29/wallzZPh.webp)